SecBot SecBot

AXSM

Axsome Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001579428 Biotech & Drug Discovery
$137.01 −4.68 (−3.30%)
Nov 16 4:00 PM ET · prev $141.69
Market cap
$7.6B
Mid cap
Consensus
Buy
93% Buy or better · 29 analysts
Median target
🔒 Subscribers only
1 year
−5.9%
from $145.56 · Nov 17
30 days
−12.1%
from $155.81
52-week range
$129.80–255.17
−46% from high · low Nov 5
Avg volume 20D
1.15M
shares / day
Short interest
3.26M
≈6.2% of shares · +4.9%
Days to cover
3.4
at average volume
Insider net
−$61.1M
0 buyers · 7 sellers · since Feb 10
New fund stakes
0
Q3 2026 13F · 6 exits
Filing reports
20
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 1 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next FDA decision date, May 1, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $61.1M.

  • InstitutionsMIXED

    Q3 2026: 37 added (0 new), 37 trimmed or exited.

  • AnalystsBULLISH

    27 of 29 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +4.9% to 3.26M shares. 3.4 days to cover, ≈6.2% of shares.

  • TrendDOWNTREND

    19% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
6
exits
FundMoveSharesValue
UBS Group AGDOUBLED849,766$156.7M
WESTFIELD CAPITAL MANAGEMENT CO LPDOUBLED725,608$133.8M
MORGAN STANLEYTRIM591,504$109.1M
FEDERATED HERMES, INC.DOUBLED482,338$88.9M
Assenagon Asset Management S.A.TRIM250,805$46.2M
DEUTSCHE BANK AG\ADD170,540$31.4M
Aberdeen Group plcADD117,432$21.7M
RAYMOND JAMES FINANCIAL INCTRIM105,806$19.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

29 analysts
Buy 93% rate it Buy or better
Strong Buy11Buy16Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 4, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Nov 3, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 3, 2026UBS
MAINTAIN
MAINTAINBuy
Nov 3, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 3, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$61.1M
sold · 7 insiders
DateInsiderTypeValue
Sep 3, 2026
Jacobson Mark L.
Chief Operating Officer
Sep 3, 2026
SELL$2.1M
Sep 3, 2026
Jacobson Mark L.
Chief Operating Officer
Sep 3, 2026
EXERCISE$129.5K
Aug 6, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Aug 6, 2026
SELL$997.0K
Aug 6, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Aug 6, 2026
EXERCISE$23.1K
Aug 5, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Aug 5, 2026
EXERCISE$222.8K
Aug 5, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Aug 5, 2026
SELL$9.5M
Jul 1, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Jul 1, 2026
EXERCISE$245.8K
Jul 1, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Jul 1, 2026
SELL$11.9M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,263,105
shares short
+4.9%
vs prior settlement
3.4
days to cover
≈6.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 2, 2026 SEC
Axsome reported Q3 2026 net product revenue of $259.7M (+52% YoY), driven by AUVELITY sales of $207.6M (+53% YoY) and…
8-K · Impact 6/10
Nov 2, 2026 SEC
Axsome Therapeutics reported Q3 2026 net product revenue of $259.7M, 52% YoY growth, beating the $249.2M consensus…
PRESS-RELEASE · Impact 6/10
Nov 2, 2026 Earnings
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth
Oct 20, 2026 SEC
Three institutional asset managers trimmed or exited AXSM positions in Q3 2026, led by Assenagon Asset Management…
INST-CLUSTER · Impact 4/10
Sep 30, 2026 Inst.
UBS Group AG · DOUBLED
849,766 shares ($156.7M)
Sep 30, 2026 Inst.
WESTFIELD CAPITAL MANAGEMENT CO · DOUBLED
725,608 shares ($133.8M)
Sep 3, 2026 Insider
Jacobson Mark L. sold 10,000 shares
Chief Operating Officer @ $208.65 ($2.1M)
Sep 3, 2026 Insider
Jacobson Mark L. acquired via exercise 10,000 shares
Chief Operating Officer @ $12.95 ($129.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

20 filings · 6 press releases · 5 bullish · 1 bearish · 4 mixed · 10 neutral
All AXSM filing & press-release reports (26)